Success Stories

Back to success stories list.

Michelson Diagnostics


Optical imaging company Michelson Diagnostics has secured £600,000 of early stage funding, enabling it to further enhance its
pioneering technology and pursue in-vivo trials in a clinical environment. This innovative, next generation imaging technology addresses the key need for clinicians to see, during an operation and in real time, the location and extent of a tumour, for a range of cancer types.

This enables faster, more accurate cancer surgery, with the associated benefits for the patient and clinician, when compared with the slow, painstaking process of taking multiple samples of tissue for analysis.

The investment round was led by investment fund London Seed Capital in conjunction with the London Business Angels and Catapult Venture Managers.

Michelson Diagnostics has the potential to significantly impact a growing market for diagnosis, treatment and post-operative monitoring of early stage cancers. Within a clinical setting the company’s technology allows surgeons to see the size and location of a tumour in real-time. This allows them to assess tumour margin and spread giving better surgical outcomes and less chance of readmission. Ex-vivo clinical testing at University College Hospital, London and Gloucestershire Royal Hospital has already demonstrated the huge potential of this new technology.

Website: www.md-ltd.co.uk